Arbutus announces abstract selected for publication at the 2022 american society of clinical oncology (asco) annual meeting

Warminster, pa., may 26, 2022 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that its abstract on a preclinical oncology study for one of arbutus' oral pd-l1 inhibitor compounds designed to reawaken the immune system, has been selected for publication at the american society of clinical oncology (asco) annual meeting being held june 3-7, 2022.
ABUS Ratings Summary
ABUS Quant Ranking